U.N. High-Level Panel On Access To Medicines’ Recommendations Jeopardize Incentives For Pharmaceutical Companies To Create New Drugs

Forbes: U.N. Health Panel Attacks IP Rights Not Viruses
Lorenzo Montanari, executive director of the Property Rights Alliance, and Philip Thompson, fellow at the Property Rights Alliance

“The U.N. High-Level Panel on Access to Medicines (UNHLP) … report attacks the ‘market-driven’ system and encourages countries to compulsory license any medicine they want …, de-link R&D costs from prices by replacing private funding with public subsidies, and re-write TRIPS Plus trade agreements. These Robin Hood policies are fanciful, erroneous, and doomed to fail. … The evidence supports protection of [intellectual property rights (IPRs)] as a key ingredient to increasing income and innovation. … [IPRs] ensure creators will have exclusive right to own and profit from their work — incentivizing continued efforts to discover and create. … The short-sighted policies recommended by the UNHLP would sacrifice … emerging pharmaceutical industries and future innovations for a stagnant present. As the U.N. revisits this issue it is hoped they also acknowledge that low- and middle-income countries have knowledge to protect as well as the follow on benefits of strong property rights” (10/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.